Somnigroup International Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Somnigroup International Inc. Common Stock trades at $62.61 (market cap $14.48B), while Twist Bioscience Corp trades at $146.17 (market cap $10.03B). The key difference: Somnigroup International Inc. Common Stock is the larger of the two by market cap, and Somnigroup International Inc. Common Stock pays a 1.08% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Somnigroup International Inc. Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| SGI | TWST | |
|---|---|---|
Market Cap | $14.48B | $10.03B |
Volume | 1,734,399 | 1,528,940 |
Sector | Consumer Cyclical | Health |
52-Week High | $97.99 | $205.00 |
52-Week Low | $61.49 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $20.78B | $9.96B |
Dividend Yield | 1.08% | — |
Signals from Pluang's Aura AI — not financial advice
Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.
SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.
Read more on SGI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →